16 October 2017Americas

Teva faces fish oil patent complaint

Irish biopharmaceutical company Amarin has continued a patent battle over its fish oil product Vascepa (icosapent ethyl), with a lawsuit targeting Teva in Nevada.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
1 April 2020   A US judge has opened the door to generic versions of heart disease drug Vascepa, after invalidating Amarin’s key patents covering the drug.

More on this story

Americas
1 April 2020   A US judge has opened the door to generic versions of heart disease drug Vascepa, after invalidating Amarin’s key patents covering the drug.

More on this story

Americas
1 April 2020   A US judge has opened the door to generic versions of heart disease drug Vascepa, after invalidating Amarin’s key patents covering the drug.